Why all patients with a pituitary mass need to be seen by an endocrinologist
For the average general practitioner, pituitary disorders are relatively uncommon. However, post-mortem and magnetic resonance imaging (MRI) studies show that about 10% of the population may harbour a pituitary mass, although most are small, non-functioning microadenomas.1 Pituitary adenomas are the commonest intracranial neoplasm, making up about 10%–15% of such lesions.2 In most large series, prolactinomas are the most prevalent subtype, at between 40% and 50%; non-functioning adenomas account for about 30%, with other functioning adenomas (secreting growth hormone, causing acromegaly; secreting adrenocorticotropic hormone, causing Cushing’s disease; or secreting glycoprotein hormones, such as intact follicle-stimulating hormone, luteinising hormone and thyroid-stimulating hormone) making up the remainder.3
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Hall WA, Luciano MG, Doppman JL, et al. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med 1994; 120: 817-820.
- 2. Kovacs K, Horvath E. Pathology of pituitary tumors. Endocrinol Metab Clin North Am 1987; 16: 529-551.
- 3. Biller BM, Swearingen B, Zervas NT, Klibanski A. A decade of the Massachusetts General Hospital Neuroendocrine Clinical Center. J Clin Endocrinol Metab 1997; 82: 1668-1674.
- 4. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev 2006; 27: 485-534.
- 5. Karavitaki N, Thanabalasingham G, Shore HC, et al. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol (Oxf) 2006; 65: 524-529.
- 6. Molitch ME. Clinical review 65. Evaluation and treatment of the patient with a pituitary incidentaloma. J Clin Endocrinol Metab 1995; 80: 3-6.
- 7. Lamberts SW, de Herder WW, van der Lely AJ. Pituitary insufficiency. Lancet 1998; 352: 127-134.
- 8. Arafah BM, Kailani SH, Nekl KE, et al. Immediate recovery of pituitary function after transsphenoidal resection of pituitary macroadenomas. J Clin Endocrinol Metab 1994; 79: 348-354.
- 9. Donovan J, Nesbit G. Distinction of masses involving the sella and suprasellar space: specificity of imaging features. AJR Am J Roentgenol 1996; 167: 597-603.
- 10. Kristof RA, Van Roost D, Klingmuller D, et al. Lymphocytic hypophysitis: non-invasive diagnosis and treatment by high dose methylprednisolone pulse therapy? J Neurol Neurosurg Psychiatry 1999; 67: 398-402.
- 11. Kaltsas GA, Powles TB, Evanson J, et al. Hypothalamo-pituitary abnormalities in adult patients with Langerhans cell histiocytosis: clinical, endocrinological, and radiological features and response to treatment. J Clin Endocrinol Metab 2000; 85: 1370-1376.
- 12. Silvani A, Eoli M, Salmaggi A, et al. Combined chemotherapy and radiotherapy for intracranial germinomas in adult patients: a single-institution study. J Neurooncol 2005; 71: 271-276.
- 13. Barker FG 2nd, Klibanski A, Swearingen B. Transsphenoidal surgery for pituitary tumors in the United States, 1996–2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab 2003; 88: 4709-4719.
- 14. Clayton RN. How many surgeons to operate on acromegalic patients? Clin Endocrinol (Oxf) 1999; 50: 557-559.
- 15. Gittoes NJ, Sheppard MC, Johnson AP, Stewart PM. Outcome of surgery for acromegaly — the experience of a dedicated pituitary surgeon. QJM 1999; 92: 741-745.
Warrick Inder has received speaker’s honoraria from Novartis Oncology and travel assistance from Novartis and Ipsen, both manufacturers of somatostatin analogues. He has also served on an advisory board for Pfizer regarding pegvisomant and human growth hormone.